 HOUSTON and VANCOUVER, BC , July 15, 2020 CNW - ESSA Pharma Inc. EPIX EPI.V, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer mCRPC patients who failed standard of care treatments, including second generation anti-androgens. EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor AR which has shown preclinical activity in both anti-androgen sensitive and anti-androgen resistant prostate cancer models. 